India To Ease Duties On Drugs

11 August 1996

The first budget of India's new government for 1996-97, presented to Parliament late last month, retains the zero rate of duty on life-saving drugs. "I also propose to reduce the rate of duty on all other allopathics from 50% to 40%," Finance Minister P Chidambaram told Parliament.

Meantime, the setting up in principle of an Indian Pharmacopoeia Commission has been agreed by the government. The Commission will work as an autonomous body to bring out new editions of the Indian Pharmacopoeia every five years.

In 1991, the government reconstituted the Indian Pharmacopoeia Committee for the preparation of the 1996 edition. Two volumes of this have just been published in New Delhi by the Minister of State for Health, Saleem Iqbal Shervani. They contain monographs for 1,149 medical substances, including 290 new drugs, and with a total of 111 deletions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight